197 related articles for article (PubMed ID: 19843089)
1. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.
Bourgault Villada I; Moyal Barracco M; Berville S; Bafounta ML; Longvert C; Prémel V; Villefroy P; Jullian E; Clerici T; Paniel B; Maillère B; Choppin J; Guillet JG
Clin Exp Immunol; 2010 Jan; 159(1):45-56. PubMed ID: 19843089
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.
Bourgault Villada I; Moyal Barracco M; Ziol M; Chaboissier A; Barget N; Berville S; Paniel B; Jullian E; Clerici T; Maillère B; Guillet JG
Cancer Res; 2004 Dec; 64(23):8761-6. PubMed ID: 15574788
[TBL] [Abstract][Full Text] [Related]
3. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.
Farhat S; Nakagawa M; Moscicki AB
Int J Gynecol Cancer; 2009 May; 19(4):508-12. PubMed ID: 19509544
[TBL] [Abstract][Full Text] [Related]
4. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
[TBL] [Abstract][Full Text] [Related]
5. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
[TBL] [Abstract][Full Text] [Related]
6. Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis.
Jabbar B; Rafique S; Salo-Ahen OMH; Ali A; Munir M; Idrees M; Mirza MU; Vanmeert M; Shah SZ; Jabbar I; Rana MA
Front Immunol; 2018; 9():3000. PubMed ID: 30619353
[TBL] [Abstract][Full Text] [Related]
7. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
[TBL] [Abstract][Full Text] [Related]
8. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
[TBL] [Abstract][Full Text] [Related]
9. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
10. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
[TBL] [Abstract][Full Text] [Related]
11. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China.
Chenzhang Y; Wen Q; Ding X; Cao M; Chen Z; Mu X; Wang T
Immunol Lett; 2017 Jan; 181():26-30. PubMed ID: 27693214
[TBL] [Abstract][Full Text] [Related]
12. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.
Al-Taei S; Banner R; Powell N; Evans M; Palaniappan N; Tabi Z; Man S
Cancer Immunol Immunother; 2013 Dec; 62(12):1821-30. PubMed ID: 24146146
[TBL] [Abstract][Full Text] [Related]
13. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.
Riemer AB; Keskin DB; Zhang G; Handley M; Anderson KS; Brusic V; Reinhold B; Reinherz EL
J Biol Chem; 2010 Sep; 285(38):29608-22. PubMed ID: 20615877
[TBL] [Abstract][Full Text] [Related]
14. HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: an in silico approach.
Yao Y; Huang W; Yang X; Sun W; Liu X; Cun W; Ma Y
Vaccine; 2013 Apr; 31(18):2289-94. PubMed ID: 23499609
[TBL] [Abstract][Full Text] [Related]
15. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
[TBL] [Abstract][Full Text] [Related]
16. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable.
Wang X; Moscicki AB; Tsang L; Brockman A; Nakagawa M
Clin Vaccine Immunol; 2008 Jun; 15(6):937-45. PubMed ID: 18448624
[TBL] [Abstract][Full Text] [Related]
17. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
18. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.
Tsang KY; Fantini M; Fernando RI; Palena C; David JM; Hodge JW; Gabitzsch ES; Jones FR; Schlom J
Vaccine; 2017 May; 35(19):2605-2611. PubMed ID: 28389098
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
